# Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation

> **NCT00144677** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (—)

## Conditions studied

- Acute Myelogenous Leukemia
- Graft Versus Host Disease
- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndromes
- Non-Hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** sirolimus
- **DRUG:** tacrolimus

## Key facts

- **NCT ID:** NCT00144677
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 30 (—)
- **Last updated:** 2012-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144677, "Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00144677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*